Cosentyx Archives -

Market Access/ News/ News

NICE backs Cosentyx’ use in thousands of children with psoriasis

Phil Taylor Cosentyx, HEOR, market access, NHS, NICE, Novartis, paediatric, psoriasis 0 Comment

NICE has recommended broadening NHS use of Novartis’ IL-17 inhibitor Cosentyx to include children aged six to 17

NICE backs Cosentyx’ use in thousands of children with psoriasis

https://pharmaphorum.com/news/nice-backs-cosentyx-use-in-thousands-of-children-with-psoriasis/

Market Access/ News/ News

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

Phil Taylor bimekizumab, Bimzelx, Cosentyx, dermatology, EU, Novartis, psoriasis, regulatory approval, UCB 0 Comment

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

https://pharmaphorum.com/news/il-17-tailender-ucb-gets-eu-ok-for-bimekizumab-in-psoriasis/

Market Access/ News/ News

NICE backs Novartis’ Cosentyx for underdiagnosed back condition

Phil Taylor axial spondyloarthritis, Cosentyx, HEOR, inflammatory diseases, NICE, Novartis 0 Comment

NICE has extended the range of indications that Novartis’ Cosentyx can be prescribed for by the NHS in

NICE backs Novartis’ Cosentyx for underdiagnosed back condition

https://pharmaphorum.com/news/nice-backs-novartis-cosentyx-for-underdiagnosed-back-condition/

News/ News/ Sales and Marketing

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilise

Phil Taylor coronavirus, Cosentyx, COVID-19, Entresto, Financial, Kisqali, Novartis, Zolgensma 0 Comment

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilise

https://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/

News/ News/ R&D/ Top stories

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trial

Phil Taylor bimekizumab, comparator clinical trials, Cosentyx, dermatology, Novartis, psoriasis, UCB 0 Comment

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug,

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trial

https://pharmaphorum.com/news/ucbs-il-17-latecomer-bimekizumab-beats-cosentyx-in-psoriasis-trial/

News/ News/ R&D

Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasis

Phil Taylor Cosentyx, Eli Lilly, mirikizumab, Novartis, psoriasis 0 Comment

Eli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate,

Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasis

https://pharmaphorum.com/news/lillys-mirikizumab-tops-novartis-blockbuster-cosentyx-in-psoriasis/

Market Access/ News/ News/ News/ R&D/ Top stories

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritis

Phil Taylor AbbVie, Cosentyx, Eli Lilly, Humira, immunology, Novartis, psoriatic arthritis, Taltz 0 Comment

Beating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritis

https://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/

News/ News/ R&D

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

Richard Staines AbbVie, ankylosing spondylitis, Cosentyx, EULAR, Novartis, psoriatic arthritis, rheumatology 0 Comment

Swiss pharma hopes to bounce back from Q1 sales disappointment

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

https://pharmaphorum.com/news/novartis-eric-hughes-cosentyx-secukinumab/

Market Access/ News/ News/ Novartis

Novartis trumpets long-term data for Cosentyx in psoriasis

Richard Staines Cosentyx, dermatology, Johnson & Johnson, Novartis, psoriasis 0 Comment

Novartis is hoping that new real world data will help its psoriasis drug Cosentyx stay ahead of rivals.

Novartis trumpets long-term data for Cosentyx in psoriasis

https://pharmaphorum.com/news/novartis-trumpets-long-term-data-cosentyx-psoriasis/

Trending

Cosentyx

Login